Journal ArticleUnknown
Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates From the ENHANCE Study (P9-19.002)
Authors
Author Affiliations
CDG Therapeutics (United States), Center for Innovation, Cleveland Clinic, EvergreenHealth, ...
Published InNeurology
Year2026
Abstract
To provide comprehensive safety data on consolidating the initial 150 mg and 450 mg doses into a single 600 mg ublituximab infusion in participants with relapsing multiple sclerosis who are treatment-naïve or transitioning from other disease modifying therapies.
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.